{"id":2506,"date":"2026-08-11T00:00:00","date_gmt":"2026-08-11T04:00:00","guid":{"rendered":"https:\/\/www.insilens.com\/?p=2506"},"modified":"2026-08-13T01:39:18","modified_gmt":"2026-08-13T05:39:18","slug":"uncoverseq-expands-crispr-off-target-nomination","status":"publish","type":"post","link":"https:\/\/www.insilens.com\/?p=2506","title":{"rendered":"UNCOVERseq Expands CRISPR Off-Target Nomination"},"content":{"rendered":"

Company:<\/strong> Integrated DNA Technologies · Event Type:<\/strong> Technology and Modalities · Product\/Asset:<\/strong> UNCOVERseq · Subject:<\/strong> CRISPR Off-Target Detection · Event Date:<\/strong> August 11, 2026<\/p>\n

\"UNCOVERseq<\/p>\n

Summary<\/h4>\n

Integrated DNA Technologies and University of California, San Francisco researchers reported UNCOVERseq, an in-cellulo workflow for nominating low-frequency CRISPR off-target sites across nucleases, high-fidelity Cas9 variants and base editors. In a benchmark set, the method achieved 97.6% sensitivity and 78% precision and was applied across 192 guide RNAs, including editing in hematopoietic stem and progenitor cells. The signal is positive\/uncertain because it improves analytical control and modality coverage, but nomination is not clinical genotoxicity validation and the authors state that the assay has not completed formal validation.<\/p>\n

What Happened<\/h4>\n

UNCOVERseq combines double-stranded DNA tag integration, RNase H-dependent PCR, blocking oligonucleotides, defined sequencing-depth requirements and computational tiering. The workflow increased usable genomic-junction reads and nominated substantially more candidate sites than the compared GUIDE-seq implementation. A promiscuous HEK293-Cas9 system was used as a sensitive proxy, followed by confirmation and translation into clinically relevant cell types. Across six selected guides, the authors compared standard and high-fidelity Cas9 and base editors in CD34-positive HSPCs. Double-strand-break nomination frequency retained rank-order concordance with base-editing off-target activity.<\/p>\n

Deep Analysis<\/h4>\n

Interpretation 1 \u2014 UNCOVERseq could improve preclinical safety packages by making off-target nomination more sensitive, controlled and reproducible across editing modalities. Supporting evidence includes benchmarked analytical performance, process controls, biological replicates and testing in HSPCs. Contradicting evidence includes 78% precision, residual dependence on sequencing depth and the possibility that a promiscuous cell proxy changes the ranking of rare events relevant in patient cells.<\/p>\n

Interpretation 2 \u2014 double-strand-break nomination may provide a useful first-pass proxy for base editors, reducing assay fragmentation. Supporting evidence is rank-order concordance between nominated DSB sites and single-strand-break-mediated base editing. Contradicting evidence is that base editors can cause modality-specific DNA and RNA changes not captured by a tag-integration workflow, and the paper itself notes that orthogonal methods may remain necessary.<\/p>\n

Evidence that would upgrade the interpretation includes formal assay validation, reproducibility across laboratories and donors, prospective use in regulatory submissions, and concordance with orthogonal genome-wide and targeted sequencing. Evidence that would downgrade it includes systematic misses in primary therapeutic cells or failure to detect clinically relevant modality-specific events. A blinded benchmark showing no advantage over established orthogonal workflows would falsify the claimed practical differentiation.<\/p>\n

Signal Extraction<\/h4>\n
    \n
  • Verified facts:<\/strong> peer-reviewed publication; 97.6% benchmark sensitivity; 78% precision; 192 guides screened; comparisons across Cas9, high-fidelity variants and base editors; HSPC experiments; defined process controls. Company-associated claim: the framework supports informed translational off-target risk assessment. Independent check: most authors are IDT employees, IDT sells related reagents and services, and the paper states the assay has not undergone full formal validation.<\/li>\n
  • Missing facts:<\/strong> inter-laboratory performance, clinical-sample reproducibility, coverage across diverse patient genomes, long-read structural-variant detection and regulatory acceptance.<\/li>\n<\/ul>\n

    Insilens Take<\/h4>\n

    UNCOVERseq is an important analytical advance because off-target nomination remains a bottleneck for programmable editing, especially as modalities diversify. Its strongest near-term role is as a sensitive nomination layer within an orthogonal safety strategy. It should not be used alone to declare an editor safe, predict patient-level genotoxicity or replace confirmation of structural variants, translocations, RNA editing and tissue-specific exposure.<\/p>\n

    Company and Product Background<\/h4>\n

    CRISPR nucleases, base editors and prime editors can create unintended changes at sites related to the intended guide sequence. Nomination assays identify candidate loci for deeper confirmation; they do not by themselves establish biological harm. HSPCs are particularly important because permanent edits can propagate through long-lived blood lineages. Regulators therefore expect sensitive, orthogonal methods tailored to the editor, delivery system, target tissue and patient genomic diversity.<\/p>\n

    Importance and Confidence<\/h4>\n

    Signal Importance: 4\/5. Signal Direction: positive\/uncertain. Confidence in Facts: high. Confidence in Interpretation: medium-high. Red-team check: the title says the method expands nomination rather than proving safety. Commercial conflicts, incomplete formal validation and the need for orthogonal confirmation are explicit.<\/p>\n","protected":false},"excerpt":{"rendered":"

    Integrated DNA Technologies and University of California, San Francisco researchers reported UNCOVERseq, an in-cellulo workflow for nominating low-frequency CRISPR off-target sites across nucleases, high-fidelity Cas9 variants and base editors. In a benchmark set, the…<\/p>\n","protected":false},"author":5,"featured_media":2505,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1,4],"tags":[319,318],"class_list":["post-2506","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-all-categories","category-technology-modalities","tag-crispr-off-target-detection","tag-integrated-dna-technologies"],"blocksy_meta":[],"_links":{"self":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/2506","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/users\/5"}],"replies":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=2506"}],"version-history":[{"count":1,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/2506\/revisions"}],"predecessor-version":[{"id":2507,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/2506\/revisions\/2507"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/media\/2505"}],"wp:attachment":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=2506"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=2506"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=2506"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}